MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

228.66 0.31

Buy Sell

Overview

Share price change

24h

Current

Min

222.13

Max

228.78

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+28.71% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-160M 13B
Previous open	228.35
Previous close	228.66

News Sentiment

By Acuity

54%

46%

296 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2026, 17:11 UTC

Major Market Movers

Major News Events

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 kwi 2026, 17:10 UTC

Major News Events

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 kwi 2026, 00:00 UTC

Major News Events

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 kwi 2026, 21:01 UTC

Major News Events

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 kwi 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Capital Finalize China JV

2 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2 kwi 2026, 20:41 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 kwi 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 kwi 2026, 20:01 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2 kwi 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 kwi 2026, 19:29 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:24 UTC

Market Talk

Major News Events

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 kwi 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 kwi 2026, 19:01 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 kwi 2026, 19:00 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 kwi 2026, 18:24 UTC

Acquisitions, Mergers, Takeovers

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 kwi 2026, 17:44 UTC

Market Talk

Major News Events

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 kwi 2026, 17:32 UTC

Major News Events

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 kwi 2026, 17:26 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 kwi 2026, 17:09 UTC

Market Talk

Major News Events

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

28.71% upside

12 Months Forecast

Average 293.77 USD 28.71%

High 342 USD

Low 255 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

296 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.